Ugolotti U, Larini P, Marcato C, Saccani A, Puccianti F, Pedretti G
Istituto di Scienze Radiologiche, Università degli Studi di Parma, Italy.
Cardiovasc Intervent Radiol. 1997 Jan-Feb;20(1):38-42. doi: 10.1007/s002709900106.
To assess the suitability of tantalum Strecker stents for transjugular intrahepatic portosystemic shunt (TIPS) creation.
TIPS was performed with Strecker balloon-expandable stents in the first 20 patients of our series. A total of 26 prostheses were utilized (average 1.3 per patient).
Immediate technical success was achieved in all 20 cases. Nine patients (45%) died during follow-up. The overall average follow-up period was 18.9 months; the 11 survivors were followed for a mean period of 29.8 months. In 4 patients (20%) the stent dislodged towards the hepatic vein during withdrawal of the balloon catheter, and difficulties in recatheterizing the shunt for routine control portal phlebography were frequently encountered. Rebleeding occurred in 5 cases and aggravation of pre-existing encephalopathy occurred in 2 cases. Shunt occlusions or stenosis required further intervention in 4 and 9 patients, respectively.
In our opinion the tantalum Strecker stent is not particularly suitable for TIPS. Although it has evident advantages, such as high radiopacity and minimal shortening after deployment, the tendency of the device to dislodge and the difficulty in recatheterization during portal phlebography were important drawbacks. Furthermore, the atraumatic ends of the device did not seem to reduce shunt-related complications, which were comparable to those occurring with other types of stent.
评估钽制施特雷克支架用于经颈静脉肝内门体分流术(TIPS)的适用性。
在我们系列研究的前20例患者中使用施特雷克球囊扩张支架进行TIPS。共使用了26个假体(平均每位患者1.3个)。
所有20例患者均立即获得技术成功。9例患者(45%)在随访期间死亡。总体平均随访期为18.9个月;11例幸存者的平均随访期为29.8个月。4例患者(20%)在撤出球囊导管时支架向肝静脉移位,在重新插入分流管进行常规门静脉造影时经常遇到困难。5例发生再出血,2例原有脑病加重。分流道闭塞或狭窄分别需要对4例和9例患者进行进一步干预。
我们认为钽制施特雷克支架不太适合TIPS。尽管它有明显的优点,如高显影性和展开后缩短最小,但该装置移位的倾向以及门静脉造影时重新插管的困难是重要的缺点。此外,该装置无创伤的末端似乎并未减少与分流相关的并发症,这些并发症与其他类型支架出现的并发症相当。